



Saving Limbs, Saving Lives

December 20, 2022

LEGAL Forward Looking Statements

This presentation includes forward-looking statements concerning our business, operations and financial performance and condition, as well as our plans, objectives and expectations for our business operations and financial performance and condition. Any statements contained in this presentation or expressed orally in connection herewith that are not statements of historical fact may be deemed to be forward-looking statements. In some cases, forward-looking statements can be identified by phrases such as "plans," "intends," "believes," "expects," "anticipates," "foresees," "forecasts," "estimates" or other words or phrases of similar import. Similarly, statements herein that describe our business strategy, outlook, objectives, plans, intentions or goals also are forward-looking statements. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Accordingly, you should not place undue reliance on our forward-looking statements. The forward-looking statements contained in this presentation or expressed orally in connection herewith are made only as of the date of this presentation and we undertake no obligation to update the forward-looking statements to reflect subsequent events or circumstances, except as required by applicable law.

None of Amsel Medical Corporation its affiliates or their respective directors, officers, employees or agents gives any representation or warranty, express or implied, as to: (i) the achievement or reasonableness of future projections, management targets, estimates or prospects contained in this presentation; or (ii) the accuracy or completeness of any information contained in this presentation, any other written information or oral information provided in connection herewith or any data that any of them generates.

This presentation was prepared by us for informational purposes only, for delivery to a limited number of parties who may be interested in exploring a potential transaction with us, and does not constitute an offer, or solicitation of an offer, to sell any securities at any time. Any securities referred to in this presentation or orally in connection herewith have not been registered under the Securities Act of 1933, as amended, or any state securities law. Such securities have not been approved or disapproved by the Securities and Exchange Commission or by any state securities regulatory authority, nor has the Securities and Exchange Commission or any such state authority passed on the accuracy or adequacy of this presentation. Any representation to the contrary is a criminal offense.

This presentation should be held in strict confidence by you and must not be photocopied or reproduced in any other electronic or physical form and its contents must not be communicated, disclosed or distributed to any other person in whole or in part.

If you wish to pursue this opportunity, you will need to rely on your own inspection and due diligence.

Certain of the information contained in this presentation may be derived from information provided by industry sources. We believe that such information is accurate and that the sources from which it has been obtained are reliable; however, we cannot guaranty the accuracy of such information and have not independently verified such information.

SAVING LIMBS, SAVING LIVES

Making Precise, highly targeted, and minimally invasive interventions possible.



"My patient had undergone varicose vein treatments as a young woman that had destroyed her leg veins, the best options for the bypass procedure she required."

- Arnold Miller, MD, FACS
Co-Founder and CMO, Amsel Medical

THE LEADERSHIP TEAM



David Doster

CEO
30 years medical
17 years AngioDynamics
Sr. VP, GM, Peripheral Division,
Resp. \$225M P&L
VP, Amer. Venous Forum



Robert Rossell

CCO
40 years Med Device
20 years AngioDynamics
Sr. VP, GM, Vascular
Access Division, Resp.
\$75M P&L



Murph McKeon

Director, Finance
Danforth Advisors
20 years Med Device
15 years Philips Healthcare
8 years finance leader with startups



Arnold Miller, MD, FACS

Co-Founder, CMO
40 years Vascular Surgeon
Pioneer of Angioscopy



Raanan Miller, PhD, MBA

Co-Founder, VP BD
20 years entrepreneurial
experience. Founder,
CTO Sionex Corporation



Jeff Willis

Sr. Director, Engineering
25+ years experience in
Sr. engineering, R&D &
manufacturing. 17 years
AngioDynamics



Lowell Kabnick MD, FACS
Vein and Lymphatic University
Former, Director NYU Vein Center



Elazer Edelman MD, PhD
Professor MIT/Brigham

MEDICAL ADVISORS



Thomas Proebstle MD
Dermatology Mainz U., Germany



Steven Schwaitzberg MD
Chair Surgery, U. Buffalo

BUSINESS MODEL



Beachhead - First to Market Product
Current FDA Cleared - Permanent Implant 
Revenue in 2023




Non-Dilutive Military Development Program
Temporary Occluder (SCureTO)
Revenue 24 mo.



FEMA

Built-in Customer Base (Military) - FEMA (Civilian/First Responders)




Licensing Opportunity
Built-in Pipeline for future growth
\$13 Billion Markets

THE PROBLEM



80 Million Adults Worldwide Affected by Progressive Venous Disease



varicose veins ➡ *leg swelling* ➡ *skin changes* ➡ *venous ulcers*

3 Million WW Procedures - \$1.5 Billion Addressable Market

THE MARKET

THE ADDRESSABLE MARKET



80 Million Adults Affected
Worldwide

Current Market

3 Million WW Procedures
\$1.5 Billion Addressable Market

\$40 Billion Market Opportunity*

* Assumes a WW device asp of \$500

THE MARKET

80 Million Patients
VENOUS DISEASE SUFFERERS



72 Million Patients
VARICOSE
VEINS

6 Million Patients
Advanced Venous
Disease

2 Million Patients
ACTIVE VENOUS
ULCERS

3 Million procedures WW
\$1.5B addressable market, 8% CAGR*



*Amsel can expand the market by 20% and take share by
drastically increasing vein center throughput*


TREATMENT STANDARD



THE CLINICAL SOLUTION

How to solve the problem

Occluding or removing the vein eliminates the pooling and swelling and allows blood to be rerouted through healthy veins.




THE SOLUTION

SCureClamp*
With interDigitatation Occlusion Technology



Technology paradigm shift in minimally invasive surgery through delivered through a small needle.




Transfixing


Atraumatic Clamping

Self Sealing

HOW IT WORKS



NON-DESTRUCTIVE CLAMPING



SCureClamp^{*} clamps the
vein without destroying it.
With interDigitation Occlusion Technology

- ➡ *Quicker procedures*
- ➡ *Less complications*
- ➡ *Less discomfort for the patient*
- ➡ *Use when other techniques aren't effective*
- ➡ *Mechanical*

SAFETY STUDY



Conducted First in Human Clinical Procedures



SCureClamp^{*}
With interDigitation Occlusion Technology

World's First Ever Percutaneous Vein Ligation

- ➡ Average Procedure Time <10 min
- ➡ High Safety Profile (12-month follow-up)
- ➡ Patient Quality Of Life Outcomes

GEN II DEVICE



SCureClamp*
With interDigitation Occlusion Technology

Gen I




SCureClamp*
With interDigitation Occlusion Technology

Gen II



Single-hand delivery development

SCureClamp GEN II END USER INPUT










Gen II End User Feedback


- 12 physicians
- Multiple Specialties
- USA/OUS

VENOUS EXIT COMPARABLES



Acquirer	Target	Mechanism	Date	Stage at M&A	Total M&A
 Medtronic	VNUS	Thermal	2009	Commercial	\$440M
 BTG	Ekos	Venous Clot	2013	FDA & CE Cleared	\$220M
 Medtronic	Sapheon VenaSeal	Glue	2014	CE Marked, Pre-FDA	\$240M
 Teleflex MEDICAL	Vascular Solutions	Thermal	2016	Commercial	\$984M
 MERITMEDICAL	Vascular Insights ClariVein	MOCA	2018	Commercial	\$60M
 Boston Scientific	Veniti	Venous Stent	2019	CE Marked, Pre-FDA	\$212M
 BD	VENCLOSE	Thermal	2021	Commercial	\$290M

DEVELOPMENT TIMELINES



Funding

Note

\$20M thru 2025






ATRAUMATIC CLAMPING



SCureClamp Needle Delivery



Clamped tissue
remains viable – No
Necrosis



Standard ligation Clip Surgical Delivery

Clamped tissue
– Necrosis

Prone to
displacement




TRAUMA

"The most significant preventable cause of death in the prehospital environment is external hemorrhage."



Temporary Occluder Arterial Injury Clamping



Non-Compressible
Junctional
Hemorrhage Sites
(Neck, Shoulders,
Groin)

*Regions where tourniquets
cannot be applied*



\$2.5 million non-dilutive
development


Battle Trauma



Natural Disaster



ER Trauma



Terrorist Attacks

Current Approaches



Gauze, Foam Pellets, Blood Clotting Compounds



For field deployment:

- Simple to deploy
- Compact
- Occlusion not localized
- Unreliable occlusion
- Post occlusion intervention needed to remove




REBOA - Resuscitative Endovascular Balloon Occlusion of the Aorta

\$17m Non-Dilutive DoD Funding



For field deployment:

- Very complex to deploy
- Does not localize occlusion
- Bulky and will not fit in M-9 medic bag



AAJT- Abdominal Aortic Junctional Tourniquet




For field deployment:

- Simple to deploy
- Non-direct compression resulting in unreliable occlusion
- Can damage organs and other tissue

❖ 87% of military fatalities occur in the prehospital environment

AMSEL'S *SCureTO*™ SOLUTION




Distal Clamp Control

Proximal Clamp Control


Clamp Release

Needle Control




STRONG IP & PUBLICATIONS

- ❖ 15 patents US and Intl.
- ❖ Multiple additional applications and provisional patents filed



- ❖ 3 Articles in peer reviewed publication



WHY NOW? We are de-risked.

- ✓ World Class Team
- ✓ 3 Focused Verticals
- ✓ Targeting Large Beachhead Market
- ✓ Strong IP – 15 Patents
- ✓ Regulatory - 3 FDA 510(k), CE Mark
- ✓ Clinical Validation
- ✓ Revenues in 2023
- ✓ Strong Exit Comparables
- ✓ Non-Dilutive Funding Support



\$8.5M Investments Raised To Date

Preferred Seed Round

Convertible Notes

Total Investor Funding **\$8.5M**

US Air Force

AFWERX

SBIR

Total Non-dilutive Funding **\$2.5M**



OPPORTUNITY

Convertible Note

\$5M with \$1.6 M Balance:

- \$9.5M Cap (15% discount)
- 6% interest

Seeking \$5M lead for Series B

CONNECT WITH US

Thank you for listening!

David W. Doster, CEO

☎ Direct: 518.796.1779

✉ ddoster@amselmedical.com

🌐 www.amselmedical.com

LinkedIn www.linkedin.com/company/amsel-medical

